Condition

Idiopathic Retroperitoneal Fibrosis clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Idiopathic Retroperitoneal Fibrosis clinical trials that are recruiting, at sites in 2 countries (most in China (2), France (1)). By phase: Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Idiopathic Retroperitoneal Fibrosis clinical trials

StudyPhaseWhereStatusRegistered
Stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis Phase 4 Agen, France and 14 other locations Recruiting Jun 23, 2022
National registry for idiopathic retroperitoneal fibrosis in China — Beijing, Beijing Municipality Recruiting Mar 19, 2020
Cohort study of idiopathic retroperitoneal fibrosis in China — Beijing, Beijing Municipality Recruiting Mar 18, 2020

All recruiting trials (3)

Quick answers

How many Idiopathic Retroperitoneal Fibrosis clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (2 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.